<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00368381</url>
  </required_header>
  <id_info>
    <org_study_id>06-05-1813</org_study_id>
    <nct_id>NCT00368381</nct_id>
  </id_info>
  <brief_title>Hydrocortisone Versus Hydrocortisone Plus Fludrocortisone for the Treatment of Adrenal Insufficiency in Severe Sepsis</brief_title>
  <official_title>A Blinded, Placebo Controlled Trial of Hydrocortisone Versus Hydrocortisone Plus Fludrocortisone for the Treatment of Adrenal Insufficiency in Severe Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CAMC Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CAMC Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the combination of hydrocortisone plus
      fludrocortisone is more efficacious than hydrocortisone alone in treating adrenal
      insufficiency in severe sepsis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sepsis is a significant cause of morbidity and mortality in critically ill patients in the
      United States. As evidenced by its increasing prevalence and high mortality rates, sepsis is
      a complex and difficult syndrome to treat. Current therapeutic management of sepsis includes
      fluid resuscitation, vasopressor and inotropic support, maintenance of oxygen delivery,
      drotrecogin alpha, and steroid replacement therapy in patients who are found to have adrenal
      insufficiency. Studies in septic patients suggest that the administration of stress doses of
      hydrocortisone alone, or the combination of hydrocortisone plus fludrocortisone promotes an
      improvement in cardiovascular performance and a quicker resolution of shock symptoms. Current
      therapeutic guidelines for the treatment of severe sepsis recommend either hydrocortisone
      alone or combination therapy with hydrocortisone and fludrocortisone as therapeutic options
      for the treatment of adrenal dysfunction in severe sepsis. This study will help determine
      which regimen is more efficacious in this patient population.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study closed for PI failure to submit renewal paperwork
  </why_stopped>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>28 days</time_frame>
    <description>All cause mortality during first 28-days after study randomization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intensive care unit survival, duration of intensive care unit stay, duration of hospitalization, survival to hospital discharge, time to vasopressor withdrawal</measure>
    <time_frame>Unable to define</time_frame>
    <description>The various secondary endpoints are patient specific serrogate markers of improvement in clinical status. Time frame for these endpoints to occur is patient specific and can not be defined for the entire study population.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Sepsis</condition>
  <condition>Adrenal Insufficiency</condition>
  <arm_group>
    <arm_group_label>Hydrocortision and fludrocortisone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study is comparing hydrocortisone alone versus the combination of hydrocortisone and fludrocortisone in the treatment of adrenal insufficiency of septic patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone</intervention_name>
    <description>Patients randomized to this arm will receive hydrocortisone for the treatment of adrenal insufficiency secondary to sepsis.</description>
    <arm_group_label>Hydrocortision and fludrocortisone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and non-pregnant females &gt; 18 years of age

          -  Patients admitted and/or pending admission to the intensive care unit

          -  Positive corticotropin stimulation test (Basal cortisol level of ≤ 34 μg/dL with Δ ≤ 9
             μg/dL after administration of 250 mg of cosyntropin)

        Patient satisfies criteria for severe sepsis Infection - one or more of the following
        criteria

          -  Documented or Suspected - positive culture results (from blood, sputum, urine, etc.)

          -  Anti-Infective Therapy - patient is receiving antibiotic, antifungal, or other
             anti-infective therapy

          -  Pneumonia - documentation of pneumonia (x-ray, etc.)

          -  WBCs - WBCs found in normally sterile .uid (urine, CSF, etc.)

          -  Perforated Viscus - perforation of hollow organ (bowel)

        SIRS - two or more of the following

          -  Temperature &gt; 38° or &lt; 36°

          -  Heart rate &gt; 90 bpm

          -  Respiratory rate above 20 breaths per minute

          -  WBC &gt; 14,000/mm3 , &lt; 4000/mm3, or &gt;10% Bands

        Acute organ dysfunction - one or more of the following

          -  Cardiovascular - SBP &lt; 90 mmHg or MAP &lt; 70 mmHg despite 20 mL/kg of fluid
             resuscitation

          -  Respiratory - PaO2/FiO2 ratio &lt; 250, PEEP &gt; 7.5, or require mechanical ventilation

          -  Renal - low urine output (eg, &lt;0.5 mL/kg/hr for 1 hour despite 20mL/kg of fluid
             resuscitation, increased creatinine (&gt;50% increase from baseline) or require acute
             dialysis

          -  Hematologic - low platelet count (&lt; 100,000/mm3) or PT/PTT &gt; upper limit of normal

          -  Metabolic - low pH with high lactate (eg, pH &lt; 7.30 and plasma lactate &gt; upper limit
             of normal

          -  Hepatic - liver enzymes &gt; 2x upper limit of normal

          -  CNS - altered consciousness or reduced Glasgow Coma Score

        Exclusion Criteria:

          -  Patients who respond to the short cosyntropin stimulation test(Δ &gt; 9mg/dL)

          -  Pregnancy or breast-feeding mother

          -  Evidence of acute myocardial infarction, meningitis, pulmonary embolism

          -  AIDS (CD4 &lt; 200 cells/mL)

          -  Contraindications for corticosteroids

          -  Formal indication for corticosteroids (specifically including patients with known
             adrenal insufficiency)

          -  Onset of shock &gt; 24 hours

          -  Etomidate administration within the 6 hours preceding randomization

          -  Cardiac arrest prior to randomization.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John A Bethea, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charleston Area Medical Center (CAMC)</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Balk RA. Severe sepsis and septic shock. Definitions, epidemiology, and clinical manifestations. Crit Care Clin. 2000 Apr;16(2):179-92. Review.</citation>
    <PMID>10768078</PMID>
  </reference>
  <reference>
    <citation>Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med. 2001 Aug 23;345(8):588-95. Review.</citation>
    <PMID>11529214</PMID>
  </reference>
  <reference>
    <citation>Dellinger RP. Cardiovascular management of septic shock. Crit Care Med. 2003 Mar;31(3):946-55. Review.</citation>
    <PMID>12627010</PMID>
  </reference>
  <reference>
    <citation>Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med. 2003 Jan 9;348(2):138-50. Review.</citation>
    <PMID>12519925</PMID>
  </reference>
  <reference>
    <citation>Vincent JL, Abraham E, Annane D, Bernard G, Rivers E, Van den Berghe G. Reducing mortality in sepsis: new directions. Crit Care. 2002 Dec;6 Suppl 3:S1-18. Epub 2002 Dec 5. Review.</citation>
    <PMID>12720570</PMID>
  </reference>
  <reference>
    <citation>Coursin DB, Wood KE. Corticosteroid supplementation for adrenal insufficiency. JAMA. 2002 Jan 9;287(2):236-40. Review.</citation>
    <PMID>11779267</PMID>
  </reference>
  <reference>
    <citation>Lamberts SW, Bruining HA, de Jong FH. Corticosteroid therapy in severe illness. N Engl J Med. 1997 Oct 30;337(18):1285-92. Review.</citation>
    <PMID>9345079</PMID>
  </reference>
  <reference>
    <citation>Marik PE, Zaloga GP. Adrenal insufficiency in the critically ill: a new look at an old problem. Chest. 2002 Nov;122(5):1784-96. Review.</citation>
    <PMID>12426284</PMID>
  </reference>
  <reference>
    <citation>Annane D. Corticosteroids for septic shock. Crit Care Med. 2001 Jul;29(7 Suppl):S117-20. Review.</citation>
    <PMID>11445745</PMID>
  </reference>
  <reference>
    <citation>Williamson DR, Lapointe M. The hypothalamic-pituitary-adrenal axis and low-dose glucocorticoids in the treatment of septic shock. Pharmacotherapy. 2003 Apr;23(4):514-25. Review.</citation>
    <PMID>12680481</PMID>
  </reference>
  <reference>
    <citation>Shenker Y, Skatrud JB. Adrenal insufficiency in critically ill patients. Am J Respir Crit Care Med. 2001 Jun;163(7):1520-3. Review.</citation>
    <PMID>11401866</PMID>
  </reference>
  <reference>
    <citation>Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. N Engl J Med. 2003 Feb 20;348(8):727-34. Review.</citation>
    <PMID>12594318</PMID>
  </reference>
  <results_reference>
    <citation>Barber AE, Coyle SM, Fischer E, Smith C, van der Poll T, Shires GT, Lowry SF. Influence of hypercortisolemia on soluble tumor necrosis factor receptor II and interleukin-1 receptor antagonist responses to endotoxin in human beings. Surgery. 1995 Aug;118(2):406-10; discussion 410-1.</citation>
    <PMID>7638758</PMID>
  </results_reference>
  <results_reference>
    <citation>van der Poll T, Barber AE, Coyle SM, Lowry SF. Hypercortisolemia increases plasma interleukin-10 concentrations during human endotoxemia--a clinical research center study. J Clin Endocrinol Metab. 1996 Oct;81(10):3604-6.</citation>
    <PMID>8855809</PMID>
  </results_reference>
  <results_reference>
    <citation>Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med. 1987 Sep 10;317(11):653-8.</citation>
    <PMID>3306374</PMID>
  </results_reference>
  <results_reference>
    <citation>Sprung CL, Caralis PV, Marcial EH, Pierce M, Gelbard MA, Long WM, Duncan RC, Tendler MD, Karpf M. The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. N Engl J Med. 1984 Nov 1;311(18):1137-43.</citation>
    <PMID>6384785</PMID>
  </results_reference>
  <results_reference>
    <citation>Lefering R, Neugebauer EA. Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med. 1995 Jul;23(7):1294-303.</citation>
    <PMID>7600840</PMID>
  </results_reference>
  <results_reference>
    <citation>Cronin L, Cook DJ, Carlet J, Heyland DK, King D, Lansang MA, Fisher CJ Jr. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med. 1995 Aug;23(8):1430-9.</citation>
    <PMID>7634816</PMID>
  </results_reference>
  <results_reference>
    <citation>Thomas JP, el-Shaboury AH. Aldosterone secretion in steroid-treated patients with adrenal suppression. Lancet. 1971 Mar 27;1(7700):623-5.</citation>
    <PMID>4101232</PMID>
  </results_reference>
  <results_reference>
    <citation>Briegel J, Forst H, Haller M, Schelling G, Kilger E, Kuprat G, Hemmer B, Hummel T, Lenhart A, Heyduck M, Stoll C, Peter K. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med. 1999 Apr;27(4):723-32.</citation>
    <PMID>10321661</PMID>
  </results_reference>
  <results_reference>
    <citation>Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med. 1998 Apr;26(4):645-50.</citation>
    <PMID>9559600</PMID>
  </results_reference>
  <results_reference>
    <citation>Annane D, Sébille V, Troché G, Raphaël JC, Gajdos P, Bellissant E. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA. 2000 Feb 23;283(8):1038-45.</citation>
    <PMID>10697064</PMID>
  </results_reference>
  <results_reference>
    <citation>Annane D, Sébille V, Charpentier C, Bollaert PE, François B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troché G, Chaumet-Riffaud P, Bellissant E. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002 Aug 21;288(7):862-71. Erratum in: JAMA. 2008 Oct 8;300(14):1652. Chaumet-Riffaut, Philippe [corrected to Chaumet-Riffaud, Philippe].</citation>
    <PMID>12186604</PMID>
  </results_reference>
  <results_reference>
    <citation>Rydvall A, Brändström AK, Banga R, Asplund K, Bäcklund U, Stegmayr BG. Plasma cortisol is often decreased in patients treated in an intensive care unit. Intensive Care Med. 2000 May;26(5):545-51.</citation>
    <PMID>10923728</PMID>
  </results_reference>
  <results_reference>
    <citation>Oelkers W. Adrenal insufficiency. N Engl J Med. 1996 Oct 17;335(16):1206-12. Review.</citation>
    <PMID>8815944</PMID>
  </results_reference>
  <results_reference>
    <citation>Zipser RD, Davenport MW, Martin KL, Tuck ML, Warner NE, Swinney RR, Davis CL, Horton R. Hyperreninemic hypoaldosteronism in the critically ill: a new entity. J Clin Endocrinol Metab. 1981 Oct;53(4):867-73.</citation>
    <PMID>6270176</PMID>
  </results_reference>
  <results_reference>
    <citation>Findling JW, Waters VO, Raff H. The dissociation of renin and aldosterone during critical illness. J Clin Endocrinol Metab. 1987 Mar;64(3):592-5.</citation>
    <PMID>3029157</PMID>
  </results_reference>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2006</study_first_submitted>
  <study_first_submitted_qc>August 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2006</study_first_posted>
  <last_update_submitted>February 10, 2012</last_update_submitted>
  <last_update_submitted_qc>February 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>CAMC Health System</investigator_affiliation>
    <investigator_full_name>Audis Bethea, Pharm.D.</investigator_full_name>
    <investigator_title>Clinical Pharmacy Specialist, Trauma/Surgery</investigator_title>
  </responsible_party>
  <keyword>sepsis</keyword>
  <keyword>septicemia</keyword>
  <keyword>sepsis syndrome</keyword>
  <keyword>adrenal insufficiency</keyword>
  <keyword>adrenal cortex hormones</keyword>
  <keyword>hydrocortisone</keyword>
  <keyword>fludrocortisone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Adrenal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Fludrocortisone</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

